Search results for " Alan"

showing 10 items of 58 documents

Investigation of applicability of alanine pellets and films for dosimetry of proton clinical beams

2015

Laser-driven proton has recently gained a great interest as an alternative to conventional and more expensive acceleration techniques. These ion beams have desirable qualities such as small source size, high luminosity and small emittance to be used in different physics fields. This is very promising specially for the future perspective of a new concept of hadrontherapy based on laser-based devices could be developed, replacing traditional accelerating machines. ELIMED (Medical Applications at Extreme Light Infrastructure) is a task-force originally born by an idea of ELI-Beams (Prague) and INFN-LNS (Italian Institute for Nuclear Physics of Catania) researchers. ELIMED main goal is to perfo…

Laser DrivenESR Alanine ELIMED ProtonSettore FIS/01 - Fisica SperimentaleSettore FIS/04 - Fisica Nucleare E SubnucleareSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)
researchProduct

Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver

2012

Background: The prevalence of hepatitis C virus infection increases with advancing age, but elderly hepatitis C virus patients remain an understudied population. Aim: To define the virological, epidemiological and clinical profiles of Italian outpatients aged 65 years and over infected by hepatitis C virus. Methods: We evaluated 1544 anti-hepatitis C virus positive patients aged >=65 years referred to 34 Italian outpatient specialty clinics over a two-year period. Results: The study population included 1134 (73%) early elderly (65-74 years) and 410 (27%) late elderly patients (>=75 years). Late elderly subjects were less likely to have their virus genotyped, their viral load assessed or a h…

Liver CirrhosisMaleAGED PATIENTS; EPIDEMIOLOGY; HCV INFECTION; LIVER DISEASES; ANTI-VIRAL TREATMENTEpidemiologyCross-sectional studyHepacivirusLIVER DISEASESmedicine.disease_causeLiver disease80 and overPrevalenceEPIDEMIOLOGYChronicAged patientsAged 80 and overeducation.field_of_studyhepatitis c elderly italyAge FactorsHCV INFECTIONGastroenterologyliver diseases; hepatitis c elderly italy; hcv infection; epidemiology; aged patientsAlanine TransaminaseHepatitis CViral LoadAGED PATIENTSHepatitis CHCV infectionItalyHCVAged patients; Epidemiology; HCV infection; Liver diseasesPopulation studyFemaleViral loadmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAHepatitis C virusPopulationgeriatricAntiviral AgentsInternal medicinemedicineHumanseducationSettore MED/42 - IGIENE GENERALE E APPLICATALiver diseasesAgedHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAHepatitis C ChronicHepatitis C AntibodiesHepatologymedicine.diseaseSurgeryCross-Sectional StudiesAged patients; Epidemiology; HCV infection; Liver diseases; Age Factors; Aged; Aged 80 and over; Alanine Transaminase; Antiviral Agents; Cross-Sectional Studies; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Male; Prevalence; Viral Load; Gastroenterology; HepatologyANTI-VIRAL TREATMENTbusiness
researchProduct

p42 MAPK phosphorylates 80 kDa MARCKS at Ser-113.

1996

Abstract It is demonstrated here that p42 MAPKinase (p42 MAPK) phosphorylates the M yristoylated A lanine- R ich C - K inase S ubstrate (MARCKS) at Ser-113. In permeabilised Swiss 3T3 cells activation of protein kinase C (PKC) leads to p42 MAPK activation, but only the protein kinase C sites in MARCKS become phosphorylated and not Ser-113. The mitogen platelet-derived growth factor (PDGF) elicits the same response. These results demonstrate that while Ser-113 is a substrate for p42 MAPK in vitro and can be phosphorylated in vivo as shown by Taniguchi et al. [(1994) J. Biol. Chem. 269, 18299–18302], its phosphorylation is not subject to acute regulation by p42 MAPK in Swiss 3T3 cells.

MAPK/ERK pathwayMARCKSmedicine.medical_treatmentMitogen-activated protein kinase kinaseBiochemistryenvironment and public healthSubstrate SpecificityMiceStructural BiologySerinep42MAPKinasePhosphorylationMyristoylated Alanine-Rich C Kinase SubstrateCells CulturedProtein Kinase CMitogen-Activated Protein Kinase 1Platelet-Derived Growth FactorbiologyChemistryIntracellular Signaling Peptides and Proteins3T3 CellsProtein-Tyrosine KinasesCell biologyBiochemistryMitogen-activated protein kinasePhosphorylationTetradecanoylphorbol Acetatebiological phenomena cell phenomena and immunityPlatelet-derived growth factor receptorhormones hormone substitutes and hormone antagonistsendocrine systemRecombinant Fusion ProteinsMolecular Sequence DataBiophysicsGeneticsmedicineAnimalsAmino Acid SequenceMARCKSMolecular BiologyProtein kinase CGrowth factorMembrane ProteinsProteinsCell BiologyPeptide FragmentsEnzyme ActivationMolecular Weightenzymes and coenzymes (carbohydrates)Calcium-Calmodulin-Dependent Protein Kinasesbiology.proteinMutagenesis Site-DirectedMitogensFEBS letters
researchProduct

Lack of Correlation between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: A Retrospective Study

2015

AbstractElevation in liver transaminases is common in patients treated with the marine antitumor agent trabectedin. However, the impact of trabectedin-related transaminase elevations on treatment outcomes is unclear. This retrospective study investigated the correlation between liver tests abnormalities and treatment outcomes in patients with unresectable advanced or metastatic soft tissue sarcomas (STS) treated with trabectedin 1.5 mg/m2 once every 3 weeks at three reference centers in Italy. The effect of grade 3/4 elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) during the first two cycles and at any time during trabectedin treatment on progression-free su…

Malemedicine.medical_treatmentSoft Tissue NeoplasmsDioxoleKaplan-Meier EstimateGastroenterologyLiver Function TestsRetrospective StudieTetrahydroisoquinolinesTetrahydroisoquinolineTrabectedinMultidisciplinarybiologymedicine.diagnostic_testLiver Function TestSoft tissue sarcomaAlanine TransaminaseSarcomaMiddle AgedLiverFemaleSarcomamedicine.drugHumanAdultmedicine.medical_specialtyDioxolesdigestive systemArticleDisease-Free SurvivalDrug Administration ScheduleTransaminaseInternal medicinemedicineHumansAspartate AminotransferasesSoft Tissue NeoplasmAntineoplastic Agents AlkylatingRetrospective StudiesAgedChemotherapybusiness.industryRetrospective cohort studyAspartate Aminotransferasemedicine.diseasedigestive system diseasesSurgeryAlanine transaminasebiology.proteinbusinessLiver function testsAdult; Aged; Alanine Transaminase; Antineoplastic Agents Alkylating; Aspartate Aminotransferases; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; MultidisciplinaryTrabectedin
researchProduct

Synthesis and Inhibitory Studies of Phosphonic Acid Analogues of Homophenylalanine and Phenylalanine towards Alanyl Aminopeptidases.

2020

A library of novel phosphonic acid analogues of homophenylalanine and phenylalanine, containing fluorine and bromine atoms in the phenyl ring, have been synthesized. Their inhibitory properties against two important alanine aminopeptidases, of human (hAPN, CD13) and porcine (pAPN) origin, were evaluated. Enzymatic studies and comparison with literature data indicated the higher inhibitory potential of the homophenylalanine over phenylalanine derivatives towards both enzymes. Their inhibition constants were in the submicromolar range for hAPN and the micromolar range for pAPN, with 1-amino-3-(3-fluorophenyl) propylphosphonic acid (compound 15c) being one of the best low-molecular inhibitors …

Models MolecularProtein Conformation alpha-HelicalMolecular modelStereochemistryPhosphorous AcidsSwinePhenylalaninelcsh:QR1-502PhenylalanineCD13 Antigenscomputer-aided simulationsInhibitory postsynaptic potential01 natural sciencesBiochemistrylcsh:MicrobiologyArticlePhenylalanine derivativesSubstrate SpecificitySmall Molecule Libraries03 medical and health sciencesStructure-Activity RelationshipAnimalsHumansProtein Interaction Domains and MotifsEnzyme Inhibitorsphosphonic acid inhibitorsMolecular Biology030304 developmental biologyAlaninechemistry.chemical_classification0303 health sciencesInhibitory potentialBinding Sites010405 organic chemistryChemistryAminobutyratesFluorineBromine0104 chemical sciencesIsoenzymesKineticsEnzymehuman and porcine alanine aminopeptidasefluorine and bromine substitutionThermodynamicsProtein Conformation beta-StrandProtein BindingBiomolecules
researchProduct

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

2020

Background & Aims NAFLD is a growing health concern. The aim of the Fatty Liver Assessment in Germany (FLAG) study was to assess disease burden and provide data on the standard of care from secondary care. Methods The FLAG study is an observational real-world study in patients with NAFLD enrolled at 13 centres across Germany. Severity of disease was assessed by non-invasive surrogate scores and data recorded at baseline and 12 months. Results In this study, 507 patients (mean age 53 years; 47% women) were enrolled. According to fibrosis-4 index, 64%, 26%, and 10% of the patients had no significant fibrosis, indeterminate stage, and advanced fibrosis, respectively. Patients with advanced fib…

NAFLD non-alcoholic fatty liver diseasemedicine.medical_specialtyBMI body mass indexNASH non-alcoholic steatohepatitisLiver fibrosisLSM liver stiffness measurementAST aspartate aminotransferaseLiver diseaseFLAG Fatty Liver Assessment in GermanyNAFLDALT alanine aminotransferaseInternal medicineAPRI aspartate-aminotransferase-to-platelet ratio indexInternal MedicineNAFL non-alcoholic fatty liverImmunology and AllergyMedicineddc:610Co-morbiditieslcsh:RC799-869FIB-4 fibrosis-4Disease burdenHepatologyFAST FibroScan-ASTGGT gamma-glutamyltransferasebusiness.industryFatty liverNASHGastroenterologyReal worldGLP-1 glucagon-like peptide-1T2DM type 2 diabetes mellitusCVE cardiovascular eventmedicine.diseaseMetabolic syndromeCohortlcsh:Diseases of the digestive system. GastroenterologyCAP controlled attenuation parameterSteatohepatitisMetabolic syndromebusinessBody mass indexResearch ArticleCohort studyJHEP Reports
researchProduct

Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis

2021

Background & Aims Progressive fibrosis has been identified as the major predictor of mortality in patients with non-alcoholic fatty liver disease (NAFLD). Several biomarkers are currently being evaluated for their ability to substitute the liver biopsy as the reference standard. Recent clinical studies in NAFLD/NASH patients support the utility of PRO-C3, a marker of type III collagen formation, as a marker for the degree of fibrosis, disease activity, and effect of treatment. Here we establish the healthy reference range, optimal sample handling conditions for both short- and long-term serum storage, and robustness for the PRO-C3 assay. Methods PRO-C3 was measured in 269 healthy volunteers…

NASH-CRN NASH Clinical Research NetworkBiopsyDiseaseAST aspartate aminotransferaseRC799-869Ethnic groupsGastroenterologyNIMBLE Non-Invasive Biomarkers of Metabolic Liver Disease (consortium)FibrosisImmunology and AllergyBody mass indexmedicine.diagnostic_testFatty liverNAS NAFLD Activity ScoreGastroenterologyDiseases of the digestive system. GastroenterologyHospitalsNPV negative predictive valueLiver biopsyBiomarker (medicine)Research Articlemedicine.medical_specialtyNAFLD non-alcoholic fatty liver diseaseADAM A Disintegrin and MetalloproteasesNASH non-alcoholic steatohepatitisReference rangeReference valuesAUROC area under the receiver operating characteristics curveInternal medicineALT alanine aminotransferaseBiopsyInternal MedicinemedicineHumansFIB-4 fibrosis-4Healthy volunteersHepatologyALP alkaline phosphatasebusiness.industryCLSI Clinical and Laboratory Standards InstituteT2DM type 2 diabetes mellitusELF™ test Enhanced Liver Fibrosis testmedicine.diseaseLITMUS Liver Investigation: Testing Marker Utility in Steatohepatitis (consortium)Collagen type IIIFibrosisPPV positive predictive valueReference standardsbusinessBody mass indexBiomarkersNon-alcoholic fatty liver disease
researchProduct

CHARACTERIZATION OF THE GAMMA DOSE COMPONENT IN THE NEUTRON FIELD OF A BNCT IRRADIATION FACILITY

2017

At the University of Pavia, a neutron irradiation facility has been constructed for preclinical in vitro and in vivo studies for BNCT. The facility is a wide channel (40 x 20 x 100 cm3) inside the graphite Thermal Column of the 250 KW research reactor TRIGA Mark II. The neutron field consists in a thermal component ranging from about 1010 and 109 cm-2s-1 along the longitudinal axis of the channel and it is uniform within 10% along the transversal axes. The fast neutron contamination (En > 1.58 keV) is more than 2 orders of magnitude lower. The gamma background coming from the core has been reduced with a 20 cm thick bismuth shield, however in the facility a gamma component is still prese…

Neutron Dosimetry Triga Pavia Alanine Monte Carlo ESRSettore ING-IND/20 - Misure E Strumentazione NucleariSettore FIS/01 - Fisica SperimentaleSettore FIS/04 - Fisica Nucleare E SubnucleareSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)
researchProduct

EPR/alanine dosimetry for two therapeutic proton beams

2016

Abstract In this work the analysis of the electron paramagnetic resonance (EPR) response of alanine pellets exposed to two different clinical proton beams employed for radiotherapy is performed. One beam is characterized by a passive delivery technique and is dedicated to the eyes treatment (OPTIS2 beam line). Alanine pellets were irradiated with a 70 MeV proton beam corresponding to 35 mm range in eye tissue. We investigated how collimators with different sizes and shape used to conform the dose to the planned target volume influence the delivered dose. For this purpose we performed measurements with varying the collimator size (Output Factor) and the results were compared with those obtai…

Nuclear and High Energy PhysicsDosimeterProtonChemistrySettore FIS/01 - Fisica SperimentaleSobpCollimatorSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)030218 nuclear medicine & medical imaginglaw.invention03 medical and health sciences0302 clinical medicineNuclear magnetic resonancePlanned Doselaw030220 oncology & carcinogenesisProton beam Alanine ESR EPR Treatment Planning System PSIPLAN SOBPDosimetryIrradiationInstrumentationBeam (structure)
researchProduct

Implementation of advanced methodologies in the commissioning of a Light Ion Beam Therapy facility

Particle TherapyMedical CommissioningTreatment Planning SystemProtonParticle Therapy; Protons; Alanine dosimetry; Monte Carlo; Medical Commissioning; Treatment Planning SystemAlanine dosimetryMonte CarloSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)
researchProduct